ARAY vs DCGO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARAY's Piotroski F-Score of 4/9 indicates weak financial health, with a critical debt-to-equity ratio of 2.90 and negative ROE of -70.32%, signaling significant operational and solvency concerns. Despite a 16.8% year-over-year revenue growth, the company remains unprofitable with a negative profit margin of -8.15% and erratic earnings performance, including a -650% YoY EPS decline. The stock trades at a deeply discounted price-to-sales of 0.10 and price-to-book of 0.82, but this reflects severe market skepticism due to persistent losses and high financial risk. Analysts have a target price of $2.52, implying a potential 580% upside, yet this is based on minimal coverage and no consensus, underscoring speculative risk. The lack of insider activity and technical bearishness further reinforce a high-risk profile.
DCGO shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
ARAY vs DCGO: Head-to-Head Comparison
This page compares Accuray Incorporated (ARAY) and DocGo Inc. (DCGO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.